PAHT leads to a stricture of the arterial lumen induced by arterial wall remodelling, cellular proliferation [6] , and a persistent vasoconstriction due to a modification of SMC function [7] associated with vascular endothelium dysfunction [8] . The resulting hypoxia and increased resistance to the blood flow in the lung results in the development of right heart ventricular dysfunction followed by death [9] .
The treatments currently used combine phosphodiesterase inhibitors [10] , endothelin receptor antagonists [11] , and prostanoids, which with their vasodilatory, anti-proliferative, anti-inflammatory, and anti-coagulant profile of effects makes them interesting substances in the treatment of PAHT [12] . Oxygen therapy and NO inhalation are also used, but they present an increased risk of reactive oxygen species generation [13] . There is no long-term treatment for this disease, and even if actual therapies allow lightening of incapacitating consequences of PAHT, lung and heart transplant remains the only solution. Currently, research is being carried out to develop newer, long-term treatments that may be less damaging for the liver and, when used in multitherapy, could offer more favourable interaction profiles.
Dehydroepiandrosterone (DHEA) was isolated for the first time in 1934 by Butenandt and Dannenbaum and extracted from human plasma later in 1944 by Migeon and Plager [14] . DHEA is a 3b-hydroxysteroid in C19 metabolised from pregnenolone [15] and its secretion from the adrenal gland decreases with ageing for humans and primates [16] .
There is actually a controversy about the plasma levels of DHEA and DHEA-sulphate in cases of coronary atherosclerosis; some studies find it increased but others show a decrease [17, 18] . Nevertheless, DHEA has many interesting properties: it has been shown to dilate arteries, to block hypoxia-induced vasoconstriction by activating potassium channels via soluble guanylate cyclase (sGC) activation [19] , and to enhance endothelial function in particular through increased nitric oxide synthesis [20] . To date, the physiological role of DHEA remains largely unknown, but it is seen by many as a potential "fountain of youth" and is freely available online as a nutritional supplement. New studies are thus overdue for the understanding of DHEA's endogenous regulatory role in the circulation and its potential use for PAHT therapy, as well as for discerning more of the physiological effects observed for a wider range of concentrations of DHEA intake [5] .
In this issue of the Journal, Oka et al. [5] have investigated the many aspects DHEA treatment has on hypoxia-induced pulmonary hypertension, and the results are promising in terms of providing leads to developing new therapies. Chronic treatment of pulmonary hypertensive rats with DHEA induces an increase of testosterone plasma levels. In return, testosterone is known to increase the carotid body sensitivity to hypoxia and to stimulate the ventilatory response to hypoxia and hypercapnia [21] . One point to consider is the effects on cardiac output observed with increasing concentrations of DHEA, especially the fact that the systolic index, which is not much different between pulmonary hypertensive rats treated or not with 1% DHEA, shows a tendency to increase back to a normal value for a treatment with 0.3% DHEA, which in contrast is less efficient against PAHT. This suggests a possible dual cardiovascular regulatory potential of DHEA with an effect on heart functionality itself, which needs further investigation especially considering the lack of regulation in the DHEA market.
Some very interesting findings were made by using DHEA not only to inhibit the development of PAHT, but to treat established PAHT [5] . Indeed, this team succeeded in recording an inhibition of PAHT, and more importantly a remission of well-established PAHT correlated with a decrease of physiological consequences on heart function and pulmonary artery remodelling. This effect seems to be due to an increased expression and activity of sGC, which increases the arterial wall response to nitric oxide, thus compensating the endothelial dysfunction induced by PAHT. Their results, by activating the sGC pathway, uncover a promising alternative pathway to NO inhalation. This study, by assessing many physiological aspects of DHEA, highlights the necessity to attach even more importance to fully understanding the endogenous role of DHEA in circulation, bringing new hopes for the development of long-term therapy against PAHT.
